301907 VO Development of novel cancer immunotherapies (2019W)

from target identification through target validation to clinical trials

Moodle

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).

Details

Language: English

Examination dates

Lecturers

Sebastian Carotta

Classes

SR 4/BZB, Dr.Bohrgasse 9/6.Stock 1030 Wien
Termine: 28.11., 29.11., 6.12., 10.01.2020 jeweils 9.00 -12.00 Uhr
Prüfung 17.1.2020 - 9.00 Uhr/SR 1

Information

Aims, contents and method of the course

Currently, promising results are being achieved in the field of cancer immunotherapy. However, not every patients is responding to the available therapies. The lecture will:
(1) give an overview on current therapies: their potential, their risks and where they currently fail: description of different therapy modalities: Antibodies (check point inhibitors, protacs, T cell engagers , neutralizing Antibodies) and small molecule therapies (inhibitors and agonists)
(2) description on how cancer imrnunotherapy targets are being discovered: available methods for target screening and how to validate them
(3) description how to validate the targets
(4) explain why biomarker research is important for the success oftherapies
(5) describe the different stages of clinical trials

Assessment and permitted materials

written exam

Minimum requirements and assessment criteria

100-87%: Sehr Gut ( I ); 87,99-75%: Gut (2); 74,99-62%: Befriedigend (3); 6 I ,99-50%: Genügend (4); < 50%: Nicht Genügend (5)

Examination topics

Reading list

Association in the course directory

MMB IV-2,MMB W-2, MMEI II-3.2,MMEI III, WZB

Last modified: We 19.08.2020 07:49